These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21118870)

  • 21. [Pregnancy in rheumatic patients treated with biologic drugs].
    Sentić M; Baresić M; Anić B; Bosnić D; Cerovec M; Mayer M; Smiljanić L; Cikes N
    Lijec Vjesn; 2010; 132(9-10):317-8. PubMed ID: 21261033
    [No Abstract]   [Full Text] [Related]  

  • 22. Mechanism of action of tumor necrosis factor antagonists. Proceedings of the Canadian expert roundtable meeting, Banff, Canada, November 28-30, 2003.
    J Rheumatol Suppl; 2005 Mar; 74():1-47. PubMed ID: 15742456
    [No Abstract]   [Full Text] [Related]  

  • 23. Advances in targeted therapies X. Preface.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii1. PubMed ID: 19022807
    [No Abstract]   [Full Text] [Related]  

  • 24. The history of the use of sulphasalazine in rheumatology.
    Amos RS
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():2-6. PubMed ID: 8535643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in targeted therapies XI.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i1. PubMed ID: 19995739
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunogenicity of TNF alpha inhibitors in rheumatology: many questions, enough answers?
    Wendling D; Verhoeven F; Guillot X; Prati C
    Expert Opin Drug Saf; 2017 Jan; 16(1):1-3. PubMed ID: 27737601
    [No Abstract]   [Full Text] [Related]  

  • 27. Robin goodfellow.
    Rheumatology (Oxford); 2002 Sep; 41(9):1081. PubMed ID: 12209049
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-tumour necrosis factor agents and lipid profile: a class effect?
    Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
    Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
    [No Abstract]   [Full Text] [Related]  

  • 29. Update in rheumatology: evidence published in 2011.
    Forbess LJ; Bass AR
    Ann Intern Med; 2012 Jul; 157(2):114-9. PubMed ID: 22801673
    [No Abstract]   [Full Text] [Related]  

  • 30. Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology.
    Brunner HI; Rider LG; Kingsbury DJ; Co D; Schneider R; Goldmuntz E; Onel KB; Giannini EH; Lovell DJ;
    Pediatr Rheumatol Online J; 2018 Jul; 16(1):45. PubMed ID: 29996857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].
    Faucherre M; Pazar B; So A; Aubry-Rozier B
    Rev Med Suisse; 2011 Jan; 7(277):75-6, 78-9. PubMed ID: 21309182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in targeted therapies XIII.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i1. PubMed ID: 22460135
    [No Abstract]   [Full Text] [Related]  

  • 33. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy?
    Winger EE; Reed JL
    J Rheumatol; 2009 Sep; 36(9):2122; author reply 2123. PubMed ID: 19738224
    [No Abstract]   [Full Text] [Related]  

  • 34. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
    Woodworth TG; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day R; Lipani J; Brooks P
    J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trials in pediatric rheumatology: comment on the editorial by Lehman.
    DeWitt EM; Ardoin SP; Rabinovich CE; Schanberg LE
    Arthritis Rheum; 2008 Apr; 58(4):1202-3; author reply 1203. PubMed ID: 18383362
    [No Abstract]   [Full Text] [Related]  

  • 36. [Evidence based medicine in rheumatology].
    Gause A; Raspe HH
    Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877
    [No Abstract]   [Full Text] [Related]  

  • 37. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology.
    Gazarian M; Tugwell P; Boers M; Bombardier C; Brooks P; Day R; Strand V; Wells G
    J Rheumatol; 1999 Jan; 26(1):207-9. PubMed ID: 9918265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-cytokine antibodies for rheumatic diseases.
    Atzeni F; Sarzi-Puttini P
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The British Society for Rheumatology Biologics Register: 6 years on.
    Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
    Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.